CalciMedica Advances Auxora and CM5480 in Pulmonary Hypertension
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. (Nasdaq: CALC) announced a private placement financing of up to approximately...
